JP2011523627A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011523627A5 JP2011523627A5 JP2011507562A JP2011507562A JP2011523627A5 JP 2011523627 A5 JP2011523627 A5 JP 2011523627A5 JP 2011507562 A JP2011507562 A JP 2011507562A JP 2011507562 A JP2011507562 A JP 2011507562A JP 2011523627 A5 JP2011523627 A5 JP 2011523627A5
- Authority
- JP
- Japan
- Prior art keywords
- ppm
- composition
- item
- percent
- aqueous fluid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000012530 fluid Substances 0.000 claims description 33
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 22
- 239000001301 oxygen Substances 0.000 claims description 22
- 229910052760 oxygen Inorganic materials 0.000 claims description 22
- 102100038497 Cytokine receptor-like factor 2 Human genes 0.000 claims description 12
- 230000000694 effects Effects 0.000 claims description 12
- 230000002757 inflammatory effect Effects 0.000 claims description 12
- 239000002086 nanomaterial Substances 0.000 claims description 12
- 210000004027 cell Anatomy 0.000 claims description 11
- 210000000170 cell membrane Anatomy 0.000 claims description 10
- 230000031146 intracellular signal transduction Effects 0.000 claims description 10
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 claims description 8
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 claims description 8
- 210000004556 brain Anatomy 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 108090000623 proteins and genes Proteins 0.000 claims description 8
- 102000004169 proteins and genes Human genes 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 7
- 230000000626 neurodegenerative effect Effects 0.000 claims description 7
- 101710194733 Cytokine receptor-like factor 2 Proteins 0.000 claims description 6
- 102000034353 G alpha subunit Human genes 0.000 claims description 6
- 108091006099 G alpha subunit Proteins 0.000 claims description 6
- 101000956427 Homo sapiens Cytokine receptor-like factor 2 Proteins 0.000 claims description 6
- 101000845170 Homo sapiens Thymic stromal lymphopoietin Proteins 0.000 claims description 6
- 102100031294 Thymic stromal lymphopoietin Human genes 0.000 claims description 6
- 239000000556 agonist Substances 0.000 claims description 6
- 239000003246 corticosteroid Substances 0.000 claims description 6
- 239000012528 membrane Substances 0.000 claims description 6
- 201000006417 multiple sclerosis Diseases 0.000 claims description 6
- 210000005036 nerve Anatomy 0.000 claims description 6
- 208000024891 symptom Diseases 0.000 claims description 6
- 229940124597 therapeutic agent Drugs 0.000 claims description 6
- 210000001578 tight junction Anatomy 0.000 claims description 6
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims description 5
- 229960004436 budesonide Drugs 0.000 claims description 5
- 230000004770 neurodegeneration Effects 0.000 claims description 5
- 208000024827 Alzheimer disease Diseases 0.000 claims description 4
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims description 4
- 208000018737 Parkinson disease Diseases 0.000 claims description 4
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 claims description 4
- 208000038016 acute inflammation Diseases 0.000 claims description 4
- 230000006022 acute inflammation Effects 0.000 claims description 4
- 108060000200 adenylate cyclase Proteins 0.000 claims description 4
- 102000030621 adenylate cyclase Human genes 0.000 claims description 4
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 claims description 4
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 4
- 239000005557 antagonist Substances 0.000 claims description 4
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 4
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 4
- 208000025698 brain inflammatory disease Diseases 0.000 claims description 4
- 210000003169 central nervous system Anatomy 0.000 claims description 4
- 208000037976 chronic inflammation Diseases 0.000 claims description 4
- 230000006020 chronic inflammation Effects 0.000 claims description 4
- 208000010877 cognitive disease Diseases 0.000 claims description 4
- 230000001419 dependent effect Effects 0.000 claims description 4
- 206010014599 encephalitis Diseases 0.000 claims description 4
- 230000003511 endothelial effect Effects 0.000 claims description 4
- 229960002848 formoterol Drugs 0.000 claims description 4
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 claims description 4
- 239000003862 glucocorticoid Substances 0.000 claims description 4
- 210000003630 histaminocyte Anatomy 0.000 claims description 4
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims description 4
- 239000003112 inhibitor Substances 0.000 claims description 4
- 229960001888 ipratropium Drugs 0.000 claims description 4
- OEXHQOGQTVQTAT-JRNQLAHRSA-N ipratropium Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 OEXHQOGQTVQTAT-JRNQLAHRSA-N 0.000 claims description 4
- 150000002617 leukotrienes Chemical class 0.000 claims description 4
- 239000003607 modifier Substances 0.000 claims description 4
- 102000005962 receptors Human genes 0.000 claims description 4
- 108020003175 receptors Proteins 0.000 claims description 4
- 229960002052 salbutamol Drugs 0.000 claims description 4
- 229960004017 salmeterol Drugs 0.000 claims description 4
- 239000003381 stabilizer Substances 0.000 claims description 4
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 claims description 4
- 102000027257 transmembrane receptors Human genes 0.000 claims description 4
- 108091008578 transmembrane receptors Proteins 0.000 claims description 4
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims description 3
- 206010061218 Inflammation Diseases 0.000 claims description 3
- 230000027455 binding Effects 0.000 claims description 3
- 229910001882 dioxygen Inorganic materials 0.000 claims description 3
- 229960002714 fluticasone Drugs 0.000 claims description 3
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 claims description 3
- 230000004054 inflammatory process Effects 0.000 claims description 3
- 230000004807 localization Effects 0.000 claims description 3
- 239000000243 solution Substances 0.000 claims description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims description 2
- NDAUXUAQIAJITI-LBPRGKRZSA-N (R)-salbutamol Chemical compound CC(C)(C)NC[C@H](O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-LBPRGKRZSA-N 0.000 claims description 2
- PFWLFWPASULGAN-UHFFFAOYSA-N 7-methylxanthine Chemical compound N1C(=O)NC(=O)C2=C1N=CN2C PFWLFWPASULGAN-UHFFFAOYSA-N 0.000 claims description 2
- 102100026802 72 kDa type IV collagenase Human genes 0.000 claims description 2
- 101710151806 72 kDa type IV collagenase Proteins 0.000 claims description 2
- RTAPDZBZLSXHQQ-UHFFFAOYSA-N 8-methyl-3,7-dihydropurine-2,6-dione Chemical class N1C(=O)NC(=O)C2=C1N=C(C)N2 RTAPDZBZLSXHQQ-UHFFFAOYSA-N 0.000 claims description 2
- 208000030507 AIDS Diseases 0.000 claims description 2
- 201000006474 Brain Ischemia Diseases 0.000 claims description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 2
- 208000005145 Cerebral amyloid angiopathy Diseases 0.000 claims description 2
- ZKLPARSLTMPFCP-UHFFFAOYSA-N Cetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 claims description 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 2
- 108010036949 Cyclosporine Proteins 0.000 claims description 2
- 108090000695 Cytokines Proteins 0.000 claims description 2
- 102000004127 Cytokines Human genes 0.000 claims description 2
- 108010072051 Glatiramer Acetate Proteins 0.000 claims description 2
- 208000023105 Huntington disease Diseases 0.000 claims description 2
- 108060003951 Immunoglobulin Proteins 0.000 claims description 2
- 108090000467 Interferon-beta Proteins 0.000 claims description 2
- 102000003996 Interferon-beta Human genes 0.000 claims description 2
- 108090001007 Interleukin-8 Proteins 0.000 claims description 2
- 102000004890 Interleukin-8 Human genes 0.000 claims description 2
- 108090000862 Ion Channels Proteins 0.000 claims description 2
- 102000004310 Ion Channels Human genes 0.000 claims description 2
- 102000004083 Lymphotoxin-alpha Human genes 0.000 claims description 2
- 108090000542 Lymphotoxin-alpha Proteins 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims description 2
- 102000002274 Matrix Metalloproteinases Human genes 0.000 claims description 2
- 108010000684 Matrix Metalloproteinases Proteins 0.000 claims description 2
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 claims description 2
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 claims description 2
- 208000019695 Migraine disease Diseases 0.000 claims description 2
- UCHDWCPVSPXUMX-TZIWLTJVSA-N Montelukast Chemical compound CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 UCHDWCPVSPXUMX-TZIWLTJVSA-N 0.000 claims description 2
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 claims description 2
- 208000024777 Prion disease Diseases 0.000 claims description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 2
- 208000006011 Stroke Diseases 0.000 claims description 2
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 2
- 102000014384 Type C Phospholipases Human genes 0.000 claims description 2
- 108010079194 Type C Phospholipases Proteins 0.000 claims description 2
- 206010052428 Wound Diseases 0.000 claims description 2
- 208000027418 Wounds and injury Diseases 0.000 claims description 2
- YEEZWCHGZNKEEK-UHFFFAOYSA-N Zafirlukast Chemical compound COC1=CC(C(=O)NS(=O)(=O)C=2C(=CC=CC=2)C)=CC=C1CC(C1=C2)=CN(C)C1=CC=C2NC(=O)OC1CCCC1 YEEZWCHGZNKEEK-UHFFFAOYSA-N 0.000 claims description 2
- FHEAIOHRHQGZPC-KIWGSFCNSA-N acetic acid;(2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 FHEAIOHRHQGZPC-KIWGSFCNSA-N 0.000 claims description 2
- 239000000739 antihistaminic agent Substances 0.000 claims description 2
- 239000007864 aqueous solution Substances 0.000 claims description 2
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 claims description 2
- 229960002170 azathioprine Drugs 0.000 claims description 2
- 230000004888 barrier function Effects 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 229910052791 calcium Inorganic materials 0.000 claims description 2
- 239000011575 calcium Substances 0.000 claims description 2
- 230000003197 catalytic effect Effects 0.000 claims description 2
- 230000021164 cell adhesion Effects 0.000 claims description 2
- 230000001413 cellular effect Effects 0.000 claims description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 2
- 229960001803 cetirizine Drugs 0.000 claims description 2
- 239000000812 cholinergic antagonist Substances 0.000 claims description 2
- 229960001265 ciclosporin Drugs 0.000 claims description 2
- 230000006999 cognitive decline Effects 0.000 claims description 2
- 229960001334 corticosteroids Drugs 0.000 claims description 2
- 229960000265 cromoglicic acid Drugs 0.000 claims description 2
- IMZMKUWMOSJXDT-UHFFFAOYSA-N cromoglycic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 claims description 2
- 229930182912 cyclosporin Natural products 0.000 claims description 2
- 229960000520 diphenhydramine Drugs 0.000 claims description 2
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 claims description 2
- 108020001507 fusion proteins Proteins 0.000 claims description 2
- 102000037865 fusion proteins Human genes 0.000 claims description 2
- 210000003976 gap junction Anatomy 0.000 claims description 2
- 239000007789 gas Substances 0.000 claims description 2
- 229960003776 glatiramer acetate Drugs 0.000 claims description 2
- 229960000890 hydrocortisone Drugs 0.000 claims description 2
- 210000000987 immune system Anatomy 0.000 claims description 2
- 102000018358 immunoglobulin Human genes 0.000 claims description 2
- 102000006495 integrins Human genes 0.000 claims description 2
- 108010044426 integrins Proteins 0.000 claims description 2
- 229960001388 interferon-beta Drugs 0.000 claims description 2
- 230000000968 intestinal effect Effects 0.000 claims description 2
- 230000003834 intracellular effect Effects 0.000 claims description 2
- 230000037041 intracellular level Effects 0.000 claims description 2
- 229950008204 levosalbutamol Drugs 0.000 claims description 2
- 239000003446 ligand Substances 0.000 claims description 2
- 229960003088 loratadine Drugs 0.000 claims description 2
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 claims description 2
- 210000004072 lung Anatomy 0.000 claims description 2
- 206010027599 migraine Diseases 0.000 claims description 2
- 208000027061 mild cognitive impairment Diseases 0.000 claims description 2
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims description 2
- 229960001156 mitoxantrone Drugs 0.000 claims description 2
- 230000004048 modification Effects 0.000 claims description 2
- 238000012986 modification Methods 0.000 claims description 2
- 229960005127 montelukast Drugs 0.000 claims description 2
- RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 claims description 2
- 229960004866 mycophenolate mofetil Drugs 0.000 claims description 2
- 229960005027 natalizumab Drugs 0.000 claims description 2
- 229960004398 nedocromil Drugs 0.000 claims description 2
- RQTOOFIXOKYGAN-UHFFFAOYSA-N nedocromil Chemical compound CCN1C(C(O)=O)=CC(=O)C2=C1C(CCC)=C1OC(C(O)=O)=CC(=O)C1=C2 RQTOOFIXOKYGAN-UHFFFAOYSA-N 0.000 claims description 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 2
- 230000003472 neutralizing effect Effects 0.000 claims description 2
- KASDHRXLYQOAKZ-ZPSXYTITSA-N pimecrolimus Chemical compound C/C([C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@@H](OC)C[C@@H](C)C/C(C)=C/[C@H](C(C[C@H](O)[C@H]1C)=O)CC)=C\[C@@H]1CC[C@@H](Cl)[C@H](OC)C1 KASDHRXLYQOAKZ-ZPSXYTITSA-N 0.000 claims description 2
- 229960005330 pimecrolimus Drugs 0.000 claims description 2
- 229920001184 polypeptide Polymers 0.000 claims description 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- 241000894007 species Species 0.000 claims description 2
- 208000020431 spinal cord injury Diseases 0.000 claims description 2
- 210000004500 stellate cell Anatomy 0.000 claims description 2
- 150000003431 steroids Chemical class 0.000 claims description 2
- 230000009885 systemic effect Effects 0.000 claims description 2
- 229960001967 tacrolimus Drugs 0.000 claims description 2
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 claims description 2
- 229960000278 theophylline Drugs 0.000 claims description 2
- LERNTVKEWCAPOY-DZZGSBJMSA-N tiotropium Chemical compound O([C@H]1C[C@@H]2[N+]([C@H](C1)[C@@H]1[C@H]2O1)(C)C)C(=O)C(O)(C=1SC=CC=1)C1=CC=CS1 LERNTVKEWCAPOY-DZZGSBJMSA-N 0.000 claims description 2
- 229940110309 tiotropium Drugs 0.000 claims description 2
- 230000002792 vascular Effects 0.000 claims description 2
- 229960004764 zafirlukast Drugs 0.000 claims description 2
- MWLSOWXNZPKENC-SSDOTTSWSA-N zileuton Chemical compound C1=CC=C2SC([C@H](N(O)C(N)=O)C)=CC2=C1 MWLSOWXNZPKENC-SSDOTTSWSA-N 0.000 claims description 2
- 229960005332 zileuton Drugs 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 21
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims 1
- 230000001387 anti-histamine Effects 0.000 claims 1
- 230000033228 biological regulation Effects 0.000 claims 1
- 230000004640 cellular pathway Effects 0.000 claims 1
- 230000007423 decrease Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- ZQDWXGKKHFNSQK-UHFFFAOYSA-N hydroxyzine Chemical compound C1CN(CCOCCO)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZQDWXGKKHFNSQK-UHFFFAOYSA-N 0.000 claims 1
- 229960000930 hydroxyzine Drugs 0.000 claims 1
- 210000004692 intercellular junction Anatomy 0.000 claims 1
- 150000002926 oxygen Chemical class 0.000 claims 1
- 230000006641 stabilisation Effects 0.000 claims 1
- 238000011105 stabilization Methods 0.000 claims 1
- 238000000034 method Methods 0.000 description 43
- 210000002390 cell membrane structure Anatomy 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 229960005205 prednisolone Drugs 0.000 description 2
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 229940092705 beclomethasone Drugs 0.000 description 1
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 229960000676 flunisolide Drugs 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- 229960001664 mometasone Drugs 0.000 description 1
- QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 229960005294 triamcinolone Drugs 0.000 description 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
Applications Claiming Priority (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4833208P | 2008-04-28 | 2008-04-28 | |
| US4834708P | 2008-04-28 | 2008-04-28 | |
| US61/048,347 | 2008-04-28 | ||
| US61/048,332 | 2008-04-28 | ||
| USPCT/US2008/081021 | 2008-10-23 | ||
| US12/256,774 | 2008-10-23 | ||
| US12/256,774 US20090227018A1 (en) | 2007-10-25 | 2008-10-23 | Compositions and methods for modulating cellular membrane-mediated intracellular signal transduction |
| PCT/US2008/081021 WO2009055614A1 (en) | 2007-10-25 | 2008-10-23 | Compositions and methods for modulating cellular membrane-mediated intracellular signal transduction |
| US12/258,210 | 2008-10-24 | ||
| US12/258,210 US20090274730A1 (en) | 2007-10-25 | 2008-10-24 | Compositions and methods for treating inflammation |
| PCT/US2008/081202 WO2009055729A1 (en) | 2007-10-25 | 2008-10-24 | Compositions and methods for treating inflammation |
| USPCT/US2008/081202 | 2008-10-24 | ||
| PCT/US2009/041852 WO2009134728A2 (en) | 2008-04-28 | 2009-04-27 | Compositions and methods for treating multiple sclerosis |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014094570A Division JP5869612B2 (ja) | 2008-04-28 | 2014-05-01 | 多発性硬化症を治療するための組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011523627A JP2011523627A (ja) | 2011-08-18 |
| JP2011523627A5 true JP2011523627A5 (https=) | 2012-06-21 |
| JP5539965B2 JP5539965B2 (ja) | 2014-07-02 |
Family
ID=43352974
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011507562A Active JP5539965B2 (ja) | 2008-04-28 | 2009-04-27 | 多発性硬化症を治療するための組成物および方法 |
| JP2014094570A Active JP5869612B2 (ja) | 2008-04-28 | 2014-05-01 | 多発性硬化症を治療するための組成物および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014094570A Active JP5869612B2 (ja) | 2008-04-28 | 2014-05-01 | 多発性硬化症を治療するための組成物および方法 |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP2282719B1 (https=) |
| JP (2) | JP5539965B2 (https=) |
| CN (1) | CN102076326B (https=) |
| AU (1) | AU2009241365B2 (https=) |
| BR (1) | BRPI0911612A2 (https=) |
| CA (1) | CA2722658C (https=) |
| MX (1) | MX337862B (https=) |
| WO (1) | WO2009134728A2 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8597689B2 (en) | 2006-10-25 | 2013-12-03 | Revalesio Corporation | Methods of wound care and treatment |
| US10125359B2 (en) | 2007-10-25 | 2018-11-13 | Revalesio Corporation | Compositions and methods for treating inflammation |
| US9745567B2 (en) | 2008-04-28 | 2017-08-29 | Revalesio Corporation | Compositions and methods for treating multiple sclerosis |
| US9523090B2 (en) | 2007-10-25 | 2016-12-20 | Revalesio Corporation | Compositions and methods for treating inflammation |
| US8980325B2 (en) | 2008-05-01 | 2015-03-17 | Revalesio Corporation | Compositions and methods for treating digestive disorders |
| CA2741336A1 (en) * | 2008-10-22 | 2010-04-29 | Revalesio Corporation | Compositions and methods for treating thymic stromal lymphopoietin (tslp)-mediated conditions |
| US8815292B2 (en) | 2009-04-27 | 2014-08-26 | Revalesio Corporation | Compositions and methods for treating insulin resistance and diabetes mellitus |
| MX2012012634A (es) * | 2010-04-30 | 2013-02-26 | Revalesio Corp | Métodos y composiciones para proteger contra agentes neurotóxicos. |
| BR112012028540A2 (pt) * | 2010-05-07 | 2016-07-26 | Revalesio Corp | composições e métodos para melhorar desempenho fisiológico e tempo de recuperação |
| JP2013533320A (ja) * | 2010-08-12 | 2013-08-22 | レバレジオ コーポレイション | タウオパチーを治療するための組成物および方法 |
| US20120263764A1 (en) * | 2011-04-13 | 2012-10-18 | Revalesio Corporation | Compositions and methods for inhibiting and/or modulating effector t-cells involved in inflammatory neurodegenerative disease |
| CN103505731A (zh) * | 2012-06-15 | 2014-01-15 | 中国药科大学 | 1型半胱氨酰白三烯受体拮抗剂在制备用于治疗阿尔茨海默病的药物中的用途 |
| US9763992B2 (en) | 2014-02-13 | 2017-09-19 | Father Flanagan's Boys' Home | Treatment of noise induced hearing loss |
| KR20240025721A (ko) * | 2015-06-15 | 2024-02-27 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | 노화와 연관된 질환을 치료하기 위한 방법 및 조성물 |
| EP3456815B1 (en) * | 2016-05-13 | 2024-07-03 | SIGMA TECHNOLOGY, Inc. | Aqueous solution capable of being administered to living body, and method for producing same |
| EP3843673B1 (en) * | 2018-08-31 | 2026-04-15 | Revalesio Corporation | An oxygenated fluid for use for the treatment of stroke |
| EP3991746A4 (en) * | 2019-06-26 | 2023-08-09 | Takeda Pharmaceutical Company Limited | TRANSFECTION METHOD |
| US11686208B2 (en) | 2020-02-06 | 2023-06-27 | Rolls-Royce Corporation | Abrasive coating for high-temperature mechanical systems |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH1157720A (ja) * | 1996-11-07 | 1999-03-02 | Honda Motor Co Ltd | 電解機能水、その製造方法及び製造装置 |
| US6386751B1 (en) | 1997-10-24 | 2002-05-14 | Diffusion Dynamics, Inc. | Diffuser/emulsifier |
| US7654728B2 (en) * | 1997-10-24 | 2010-02-02 | Revalesio Corporation | System and method for therapeutic application of dissolved oxygen |
| US6426066B1 (en) * | 2000-01-12 | 2002-07-30 | California Pacific Labs, Inc. | Use of physiologically balanced, ionized, acidic solution in wound healing |
| PL365909A1 (en) | 2000-02-21 | 2005-01-10 | Astrazeneca Ab | Piperidine- and piperazine substituted n-hydroxyformamides as inhibitors of metalloproteinases |
| EP1357920B1 (en) * | 2001-02-01 | 2007-09-05 | Hydron Technologies Inc. | Compositions and method of tissue superoxygenation |
| SE0100902D0 (sv) | 2001-03-15 | 2001-03-15 | Astrazeneca Ab | Compounds |
| US7396441B2 (en) * | 2002-02-22 | 2008-07-08 | Aqua Innovations, Inc. | Flow-through oxygenator |
| US20030232114A1 (en) * | 2002-06-13 | 2003-12-18 | Nikola Dekleva | Method for liquid enrichment with oxygen and applications of enriched liquids |
| AU2002321678A1 (en) * | 2002-09-09 | 2004-03-29 | Boros Béla | Oxygen-enriched water, treated within a magnetic field and heavy water |
| NZ543102A (en) | 2003-04-24 | 2008-12-24 | Incyte Corp | Aza spiro alkane derivatives as inhibitors of metalloproteases |
| JP4144669B2 (ja) * | 2004-03-05 | 2008-09-03 | 独立行政法人産業技術総合研究所 | ナノバブルの製造方法 |
| SE0400850D0 (sv) | 2004-03-30 | 2004-03-31 | Astrazeneca Ab | Novel Compounds |
| SE0403086D0 (sv) | 2004-12-17 | 2004-12-17 | Astrazeneca Ab | Compounds |
| CA2513350A1 (en) * | 2005-03-02 | 2006-09-02 | Sydney West Area Health Service | Treatment for multiple sclerosis |
| WO2007087637A2 (en) | 2006-01-26 | 2007-08-02 | Washington State University Research Foundation | Compositions and methods using matrix metalloproteinase (mmp) inhibitors for treating cognitive impairment characterized by persistent or sustained mmp expression and/or activity |
| WO2008018932A2 (en) * | 2006-05-01 | 2008-02-14 | The Board Of Trustees Of The Leland Stanford Junior University | Method and use of nano-scale devices for reduction of tissue injury in ischemic and reperfusion injury |
| JP5491185B2 (ja) * | 2006-10-25 | 2014-05-14 | リバルシオ コーポレイション | 傷のケアおよび処置の方法 |
| US8597689B2 (en) | 2006-10-25 | 2013-12-03 | Revalesio Corporation | Methods of wound care and treatment |
| AU2007308838B2 (en) | 2006-10-25 | 2014-03-13 | Revalesio Corporation | Mixing device and output fluids of same |
| EP2215260A4 (en) * | 2007-10-25 | 2011-04-20 | Revalesio Corp | COMPOSITIONS AND METHOD FOR MODULATING CELL MEMBRANE-IMPROVED INTRA-CELLULAR SIGNAL TRANSMISSION |
| CA2741336A1 (en) * | 2008-10-22 | 2010-04-29 | Revalesio Corporation | Compositions and methods for treating thymic stromal lymphopoietin (tslp)-mediated conditions |
-
2009
- 2009-04-27 AU AU2009241365A patent/AU2009241365B2/en active Active
- 2009-04-27 WO PCT/US2009/041852 patent/WO2009134728A2/en not_active Ceased
- 2009-04-27 JP JP2011507562A patent/JP5539965B2/ja active Active
- 2009-04-27 CN CN200980124930.5A patent/CN102076326B/zh active Active
- 2009-04-27 BR BRPI0911612A patent/BRPI0911612A2/pt not_active IP Right Cessation
- 2009-04-27 MX MX2010011846A patent/MX337862B/es active IP Right Grant
- 2009-04-27 EP EP09739530.5A patent/EP2282719B1/en active Active
- 2009-04-27 CA CA2722658A patent/CA2722658C/en active Active
-
2014
- 2014-05-01 JP JP2014094570A patent/JP5869612B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011523627A5 (https=) | ||
| JP2014511879A5 (https=) | ||
| JP2012506451A5 (https=) | ||
| JP2012525396A5 (https=) | ||
| JP2011500854A5 (https=) | ||
| CA2798127A1 (en) | Methods and compositions for protecting against neurotoxic agents | |
| JP2011500847A5 (https=) | ||
| Greiner et al. | Overview of the treatment of allergic rhinitis and nonallergic rhinopathy | |
| US20040053902A1 (en) | Novel composition and method for treatment of upper respiratory conditions | |
| PH12012501480A1 (en) | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| JP2012506453A5 (https=) | ||
| ES2704984T3 (es) | Composiciones para inhalación | |
| Meltzer | Allergic rhinitis: managing the pediatric spectrum | |
| EP2682101B1 (en) | Inhalation Compositions Comprising Glucose Anhydrous | |
| WO2005030331A1 (en) | Combination antihistamine medication | |
| WO2014007770A2 (en) | Inhalation compositions comprising corticosteroid and sorbitol | |
| JP2017531044A5 (https=) | ||
| JP2001508034A (ja) | 鼻ポリープの治療におけるｈ▲上＋▼，ｋ▲上＋▼―ａｔｐアーゼ阻害剤の使用 | |
| JP2007506681A5 (https=) | ||
| JP2016516762A5 (https=) | ||
| RU2006113701A (ru) | Лечение респираторных заболеваний антителами против рецептора il-2 | |
| CN102416179B (zh) | 用于哮喘的吸入性复方组合物 | |
| WO2009137087A3 (en) | A method for preventing or alleviating the noxious effects resulting from toxicant exposure | |
| JP2007518817A (ja) | 処置方法 | |
| CN112839633A (zh) | 包含药剂的低共熔溶剂及其制造方法和用途 |